Hefei Hengxin Life Science and Technology Co., Ltd. (301501) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hefei Hengxin Life Science and Technology Co., Ltd. stock ¥28.31, price ¥23.87, upside +18.6%, quality 32 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
20‑month range ¥22.70 – ¥66.37 · fair‑value band ¥21.22 – ¥35.38 · the ¥23.87 price screens below the ¥28.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Hefei Hengxin Life Science and Technology Co. in your weekly email
Every Wednesday you see whether Hefei Hengxin Life Science and Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hefei Hengxin Life Science and Technology Co., Ltd. engages in the research and development, production, and sale of polylactic acid products in China, North America, Europe, Australia, and internationally.
Show moreShow less
It offers paper and clear cups, cup lids, knives, forks, spoons, straws, stirring roads, foaming tableware, food packaging containers, packing bags, cup holders, and cup sleeves. The company was incorporated in 1997 and is based in Hefei, China.
Stock analysis
Hefei Hengxin Life Science and Technology Co., Ltd. (301501) currently trades at ¥23.87, while our model-based Fair Value estimate is ¥28.31, implying the stock looks roughly 16% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥41.07 per share, and 9 of the 16 models we run sit above the ¥23.87 price.
Bear case: the Asset-Based group reads lowest at ¥3.14, and 7 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥21.22 (bear) to ¥35.38 (bull), the price of ¥23.87 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Consumer Cyclical sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hefei Hengxin Life Science and Technology Co., Ltd. reported revenue of 1.8B CNY in FY2025 versus 719M CNY in FY2021, a compound +26.6%/yr. Reported net income was 224M CNY in FY2025, compounding +29.2%/yr from FY2021.
Key figures
Market cap 3.5B CNY (≈ $530M) Small · P/E ratio 21.5 · P/S ratio 1.85 · EPS (TTM) ¥1.11 · Dividend yield 1.5% · Net margin 8.4% · Return on equity 7.8% · Return on assets (EBIT) 30.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at −24% fair-value upside, at 19%, 301501 screens cheaper than that median.
Fair Value models
Bear¥21.22Fair Value ¥28.31Bull¥35.38
Price ¥23.87 · Upside +18.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.6496 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income¥11.62¥12.61¥14.6473
EPV¥11.87¥13.14¥14.1971
ROIC Compounder¥11.87¥13.14¥14.1969
All 16 models by family
Earnings-Based
Graham-Dodd¥10.29¥69.35¥97.1760
Lynch FV¥20.32¥29.03¥37.7458
PEG = 1.0¥20.32¥29.03¥37.7455
EPV¥11.87¥13.14¥14.1971
Dividend Discount
Gordon GGM¥2.89¥4.96¥6.5765
DDM Multi-Stage¥2.89¥4.64¥5.3365
Multiples
P/E Multiple¥24.97¥33.30¥41.6263
P/S Multiple¥19.30¥25.73¥32.1658
P/B Multiple¥45.62¥60.82¥76.0355
EV/EBIT¥21.58¥28.90¥36.2366
EV/EBITDA¥25.46¥34.08¥42.6967
EV/Revenue¥15.29¥22.01¥28.7353
Asset-Based
NCAV (Graham)¥2.07¥3.14¥3.9255
Economic Profit
Residual Income¥11.62¥12.61¥14.6473
ROIC Compounder¥11.87¥13.14¥14.1969
Growth Earnings
Growth-Adj P/E¥28.75¥41.07¥53.3965
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+17.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+15.9%
Dividend (yield on the price)1.5%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.100% → 14%
Compare Hefei Hengxin Life Science and Technology Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaging & Containers · 259 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside+18.6% · Above median
Profitability
Return on equity (12 months)7.8% · Above median
Return on assets7.8% · Top 25%
Net margin (12 months)8.4% · Top 25%
Operating margin (12 months)5.6% · Below median
Growth and dividend
Revenue growth (quarter YoY)7.3% · Below median
Dividend yield (12 months)1.5% · Below median
Balance sheet
Debt / equity0.03× · Lowest 25%
Valuation Multiplesvs Packaging & Containers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hefei Hengxin Life Science and Technology Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/301501
Frequently asked questions
Is Hefei Hengxin Life Science and Technology Co., Ltd. (301501) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥28.31 versus a price of ¥23.87, about +19% upside (undervalued).
What is the fair value of 301501?
Our model-based fair value for Hefei Hengxin Life Science and Technology Co., Ltd. is ¥28.31 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥23.87.
What is the quality score of 301501?
Hefei Hengxin Life Science and Technology Co., Ltd. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
Our model-based price target is the fair value of ¥28.31 (as of Nov 7, 2026) from 16 valuation models. Cautious scenario ¥21.22, optimistic scenario ¥35.38. It is a calculation from audited fundamentals, not an analyst target.
What is the Hefei Hengxin Life Science and Technology Co., Ltd. stock forecast for 2026?
Our models put fair value at ¥28.31, about +19% upside versus a price of ¥23.87 (undervalued). Cautious scenario ¥21.22, optimistic scenario ¥35.38. The calculation is refreshed regularly with new filings.
What is the revenue of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
Hefei Hengxin Life Science and Technology Co., Ltd. reported trailing-twelve-month revenue of about 1.9B CNY (latest available figure, as of Nov 7, 2026).
Does Hefei Hengxin Life Science and Technology Co., Ltd. pay a dividend?
Hefei Hengxin Life Science and Technology Co., Ltd. currently shows a dividend yield of 1.47% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Hefei Hengxin Life Science and Technology Co., Ltd. (301501) and when is the ex-dividend date?
Hefei Hengxin Life Science and Technology Co., Ltd. pays a dividend of ¥0.35 per share a year, a dividend yield of 1.5%. The last ex-dividend date was Jun 5, 2026. The payout ratio is 31.5% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hefei Hengxin Life Science and Technology Co., Ltd. it is ¥28.31 per share (as of Nov 7, 2026), against a price of ¥23.87. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Hefei Hengxin Life Science and Technology Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 301501 trades below its calculated fair value: price ¥23.87, fair value ¥28.31, a gap of about +19% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301501?
No. The price is what the market pays today (¥23.87); the fair value is what the company's own numbers justify (¥28.31). For Hefei Hengxin Life Science and Technology Co., Ltd. the two are ¥4.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hefei Hengxin Life Science and Technology Co., Ltd. worth?
The market values Hefei Hengxin Life Science and Technology Co., Ltd. at about 3.5B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥23.87; our models calculate a fair value of ¥28.31 per share.
What do the bullish and bearish scenarios say about 301501?
Our models span a range for Hefei Hengxin Life Science and Technology Co., Ltd.: cautious scenario ¥21.22, base ¥28.31, optimistic ¥35.38 per share (as of Nov 7, 2026, price ¥23.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301501?
Hefei Hengxin Life Science and Technology Co., Ltd. trades at a price-to-earnings ratio of 21.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥28.31 is built from several models across several years. Other multiples: P/B 1.7, P/S 1.8, EV/EBITDA 10.7.
How solid is the balance sheet of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
Balance-sheet figures for Hefei Hengxin Life Science and Technology Co., Ltd. (as of Nov 7, 2026): return on equity 7.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 301501 from its 52-week high?
Hefei Hengxin Life Science and Technology Co., Ltd. trades at ¥23.87, about 49% below its 52-week high of ¥47.08 and 5% above the low of ¥22.70 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥28.31 is for.
Which stocks are comparable to Hefei Hengxin Life Science and Technology Co., Ltd.?
From the same area (Consumer Cyclical) we also value Smurfit Westrock Plc,, Packaging Corporation, Amcor plc, International Paper Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hefei Hengxin Life Science and Technology Co., Ltd. stock attractive at the current price?
The data as of Nov 7, 2026: price ¥23.87, calculated fair value ¥28.31 (+19%), Quality Score 32/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301501 calculated?
We run Hefei Hengxin Life Science and Technology Co., Ltd. through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥28.31 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Hefei Hengxin Life Science and Technology Co., Ltd. currently trades 16% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
The closing price on Nov 6, 2026 was ¥23.87. Our model-based fair value is ¥28.31, about +19% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hefei Hengxin Life Science and Technology Co., Ltd. right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Hefei Hengxin Life Science and Technology Co., Ltd.
How large is the market capitalisation of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
The market capitalisation of Hefei Hengxin Life Science and Technology Co., Ltd. is 3.5B CNY (≈ $530M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
The price-to-sales ratio of Hefei Hengxin Life Science and Technology Co., Ltd. is 1.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
Earnings per share at Hefei Hengxin Life Science and Technology Co., Ltd. are ¥1.11 (price ÷ EPS = P/E 21.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
The dividend yield of Hefei Hengxin Life Science and Technology Co., Ltd. is 1.5% (payout 31.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
The net margin of Hefei Hengxin Life Science and Technology Co., Ltd. is 8.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
The return on equity (ROE) of Hefei Hengxin Life Science and Technology Co., Ltd. is 7.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
On an EBIT basis the return on assets of Hefei Hengxin Life Science and Technology Co., Ltd. is 30.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
The operating margin of Hefei Hengxin Life Science and Technology Co., Ltd. is 5.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
Revenue at Hefei Hengxin Life Science and Technology Co., Ltd. is growing +7.3% versus a year earlier (3y avg +19.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hefei Hengxin Life Science and Technology Co., Ltd. (301501)?
Earnings per share at Hefei Hengxin Life Science and Technology Co., Ltd. are growing −39.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hefei Hengxin Life Science and Technology Co., Ltd. (301501) generate?
The free cash flow of Hefei Hengxin Life Science and Technology Co., Ltd. is −188M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hefei Hengxin Life Science and Technology Co., Ltd. (301501) carry?
The net debt of Hefei Hengxin Life Science and Technology Co., Ltd. is 57.5M CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hefei Hengxin Life Science and Technology Co., Ltd. in the live analysis
One click puts Hefei Hengxin Life Science and Technology Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026